Quantum-Si Incorporated (QSI) Q3 2024 Earnings Call Transcript Summary
Quantum-Si Incorporated (QSI) Q3 2024 Earnings Call Transcript Summary
Net loss for the quarter amounted to $25.3 million, and adjusted EBITDA was negative $24.5 million.The following is a summary of the Quantum-Si Incorporated (QSI) Q3 2024 Earnings Call Transcript:
以下是Quantum-Si Incorporated（QSI）2024年第三季度業績會實錄摘要：
Financial Performance:
財務表現：
Third quarter 2024 revenue was below expectations at $787,000.
Gross profit was $367,000 and gross margin stood at 47%.
Net loss for the quarter amounted to $25.3 million, and adjusted EBITDA was negative $24.5 million.
2024年第三季度營業收入未達預期，爲$787,000。
毛利潤爲$367,000，毛利率爲47%。
本季度淨虧損金額達到$2530萬，調整後的EBITDA爲負$2450萬。
Business Progress:
業務進展：
Significant strides in commercial ramp-up of 'Platinum', aiming to lead the proteomics market.
Introduced key strategic hires and improved sales process to accelerate commercial adoption.
Added new library preparation and barcoding kits enhancing functionality and reduction in sample prep time.
Received the Technology Innovation Leadership Award from Frost & Sullivan for pioneering proteomic research.
Partnered with University of California, Santa Cruz, to integrate Platinum with genomic and transcriptomic data.
在'鉑金'商業推廣方面取得重大進展，旨在領導蛋白質組學市場。
引入重要戰略人才並改進銷售流程，加快商業採用。
新增了新的文庫製備和條形碼套件，增強功能性，並減少樣本準備時間。
因開創性蛋白質組學研究而從Frost & Sullivan獲得了技術創新領導獎。
與加利福尼亞大學聖克魯茲分校合作，將鉑金與基因組和轉錄組數據整合。
Opportunities:
機會：
Positioned to benefit from potential end year capital spending boosts in the industry.
New advancements in technology expected to open large, new market opportunities and position the company prominently in proteomics.
定位能夠受益於行業在年底可能出現的資本支出激增。
預計科技領域的新進展將開啓大量新的市場機會，並使公司在蛋白質組學領域處於突出地位。
Risks:
風險：
Significant lengthening of the sales cycle experienced, with some deals being pushed back, impacting revenue predictability.
銷售週期顯著延長，一些交易被推遲，影響了營業收入的可預測性。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。
